Bi-specific fusion proteins

US9238080B2 · kind B2 · utility

Assignee

• Merrimack Pharmaceuticals, Inc. · US

Inventors

• Ulrik Nielsen · Quincy, US
• Thomas Wickham · Groton, US
• Birgit Schoeberl · Cambridge, US
• Brian Harms · Brookline, US
• Bryan Linggi · Richland, US
• Matthew Onsum · Corona, US
• Byron DeLaBarre · Arlington, US
• Shaun M. Lippow · Somerville, US

Key dates

• Filing date: May 20, 2011
• Grant date: Jan 19, 2016
• Expiry date: May 20, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/80
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.